— Public comment period open until November 11, 2026 —

BOSTON, October 15, 2026 – The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of two new treatments: nomlabofusp (Larimar Therapeutics, Inc.) and omaveloxolone (Skyclarys®, Biogen Inc.) for Friedreich’s Ataxia, a rare, genetic disorder.  

Downloads: Draft Evidence Report | Draft Voting Questions

This preliminary draft marks the midpoint of ICER’s eight-month process of assessing this treatment, and the findings within this document should not be interpreted to be ICER’s final conclusions.

Submit a Public Comment

The Draft Evidence Report and Draft Voting Questions are now open to public comment:

  • All stakeholders are invited to submit formal comments by email to [email protected], which must be received by 5 PM ET on November 11, 2026.
  • ICER will review all comments and incorporate any necessary changes in the Evidence Report and Revised Voting Questions that will be posted on or about December 10, 2026.
  • All comments and ICER’s response to comments will be posted publicly along with the Evidence Report.

Please submit public comments as a Word document in the following format:

  • 12-point Times New Roman font
  • Five-page maximum (not including references or appendices)

ICER materials that provide additional detail on what types of information may be most informative to the report:

Register for the Virtual Public Meeting

On January 21, 2027, the Evidence Report will be the subject of a virtual public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). Registration for the virtual public meeting is now open.

Request to Comment at ICER’s Public Meeting

During the virtual public meeting, there will be a limited amount of time available for interested stakeholders to comment on the report:

  • Requests to submit oral comments must be emailed to [email protected] by 5 PM ET on November 11, 2026.
  • Individuals who wish to make comments must separately register to attend the meeting. For more information, please visit our website.

ICER Analytics Subscribers: Register for ICER’s Early Insights Webinar

On November 5, as part of ICER’s Early Insights Webinar Series, ICER’s President and Chief Executive Officer, Sarah K. Emond, MPP and Chief Medical Officer, David Rind, MD, MSc, will present the initial findings of this draft report. This webinar is exclusively available to all users of the ICER Analytics platform; registration for the webinar is now open.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs. For more information about ICER, please visit www.icer.org.